HC Wainwright & Co. Maintains Buy on Liquidia, Raises Price Target to $65
HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target from $58 to $65.
Stocks · News reference
United Therapeutics' Tyvaso Outlook Faces Near-Term Pressure After Liquidia Settlement, RBC Says
RBC analysts noted that United Therapeutics' outlook for its Tyvaso product faces near-term pressure following a settlement agreement with Liquidia.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasdaq Dips Over 400 Points; Bank of America Shares Tumble After Q3 Results
US stocks fell Wednesday as Nasdaq dropped 1.54% and Dow 0.35%; Bank of America sank 5% after weak results, while oil rose and inflation topped forecasts.
Wells Fargo Maintains Equal-Weight on Liquidia, Raises Price Target to $33
Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Equal-Weight and raises the price target from $30 to $33.